Healthcare is undergoing a genomics revolution, and Intellia Therapeutics (NASDAQ: NTLA) is leading the way. Founded by Jennifer Doudna, who won the 2020 Nobel Prize in Chemistry for her CRISPR-Cas9 genome editing discovery, Intellia shook the world last month. 

In a June 26 press conference, Intellia and its partner Regeneron (NASDAQ: REGN) announced "the first-ever clinical data supporting safety and efficacy of in vivo (in the body) CRISPR genome editing in humans." That rather bland scientific statement should actually send a shiver down your spine. It's now possible to use a "one-and-done" procedure to treat and even cure some deadly genetic diseases.

Image Source: Getty Images.

Continue reading

Source Fool.com